Daniel RIFFET/Photononstop via Getty Images For many years, the price of cocoa drifted in a relatively well-defined range. As late as 2020, I wrote about trading that range from my perspective as a cocoa permabull. Unfortunately, liquidity in the iPath® Bloomberg Cocoa Subindex Total Return(SM) ETN (NIB) dried up over time, and NIB was finally…
baona On 10th Aug 2023, Tapestry, Inc. (TPR) and Capri Holdings Limited (NYSE:CPRI) announced that they had reached a definitive agreement under which Tapestry would acquire Capri, providing Capri shareholders with $57 per share, a 65% premium to the prior closing at the time, and valuing the company at $8.5bn on an enterprise value basis….
Michael Vi The remarkable ascent of Palantir Technologies’ stock (NYSE:PLTR) in the past year, spurred by growing investor confidence and significant government contracts, marks a significant shift from the skepticism highlighted in my initial analysis. To delve deeper into this transformation: Investor Confidence and Market Dynamics: Palantir has captivated retail investors, particularly enthused by its…
tang90246 In a previous analysis, we analyzed the performance disparity, over a decade, between brands like Louis Vuitton (OTCPK:LVMUY), Lululemon (LULU), Tapestry (NYSE:TPR), and Ralph Lauren (RL). LVMH’s clear success reflects their ability to consistently buy brands and integrate them into their network, while always elevating the brand through French-made craftsmanship and no discounting pricing…
bjdlzx I initially started coverage of Range Resources (NYSE:RRC) back in February of 2023 with a “Hold” rating, saying that low natural gas prices were likely to hamper the company the rest of the year. Gas prices have been pretty weak, but RRC’s stock has managed to gain over 40% since my write-up. Let’s catch…
The intertwining stories of Tim Draper, a venture capitalist with an unyielding belief in Bitcoin, and Ross Ulbricht, the infamous creator of the Silk Road, present a compelling exploration of ethics, empathy, and the unpredictable nature of the cryptocurrency market. This narrative delves deep into the moral quandaries posed by their unique circumstances, offering a…
Tom Williams/CQ-Roll Call, Inc. via Getty Images Nvidia Corporation (NYSE:NVDA) reports earnings on 2/21/2024 during or after market hours. Consensus analyst estimates are for $4.56 in normalized EPS and $4.19 in GAAP EPS. Analysts expect revenue to come in at $20.33 billion. The stock has been roaring to the point that it is all everyone…
Over the past months, Bitcoin ETFs dominated the cryptocurrency, finance, and investing discourse. A flurry of attention-focused articles on the latest wave of spot Bitcoin ETF applications captured the collective interest. Stakeholders speculated on their implications. Following heightened anticipation at the beginning of 2024, the Securities and Exchange Commission of the United States (US SEC)…
SmileStudioAP Investment Thesis Zscaler’s (NASDAQ:ZS) Chief Operating Officer has resigned, effective immediately. Given that Zscaler has succeeded in once again reigniting its traction and revenue growth rates, I declare that investors should look beyond this resignation as a material detraction from the bull case and instead focus on the company’s underlying prospects. According to my…
FatCamera/E+ via Getty Images Amid the volatile terrain that is biopharmaceuticals, Day One Biopharmaceuticals (NASDAQ:DAWN) is a leader when it comes to pediatric oncology. Day One, through its lead candidate, tovorafenib, has positioned itself as a player committed to addressing the unmet needs of pediatric cancer patients, and it has been progressing through clinical trials…
da-kuk In this article, I provide a brief update on the WisdomTree International High Dividend Fund (NYSEARCA:DTH), outlining its characteristics, the current market trends, and how the ETF might perform in 2024. From my point of view, 2024 could be less exciting for the stock market than anticipated. Factors such as geopolitical tensions, presidential elections…
beast01 At a Glance Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “closed the gap” following my last update and “Buy” recommendation in October. Seeking Alpha The late October dip was at the expense of EMBARK data, which missed its primary endpoint but hit important secondary endpoints. Investors likely overreacted, leading to a sudden and staggering 42% decline….
After FTX collapsed, scornful critics widely ridiculed Caroline Ellison’s approach to stop losses. ‘I just don’t don’t think they’re an effective risk management tool,’ she infamously told an audience during FTX’s heyday. But did she have a point? Venturing into the crypto asset management realm presents a unique set of challenges that differ widely from…
EvgeniyShkolenko/iStock via Getty Images Investment thesis Our current investment thesis is: Leidos is positioned to achieve healthy long-term growth, owing to its focus on government contracts in sectors of resilience and ones that are benefiting from tailwinds. Underpinning this is deep expertise and a competitive pricing/margin structure. The company does not look overly competitive relative…
airdone The healthcare sector is chock-full of lucrative opportunities ranging from highly speculative biotech plays to blue-chip dividend aristocrats. I have an interest in the full spectrum of healthcare tickers and have a curiosity about every industry in the sector attempting to find every possible linkage to the highly profitable sector. However, I have ventured…
Love Employee At a Glance bluebird bio’s (NASDAQ:BLUE) recent FDA approval of Lyfgenia (lovo-cel), a development I’ve previously analyzed, marks a continued advancement in sickle cell disease [SCD] treatment. Notably, since my last analysis, the company has transitioned from seeking approval to facing the real-world challenges of commercialization. These include Lyfgenia’s high cost and black…
Cryptocurrencies have been around for over a decade; yet, it’s only in recent years that the mainstream has recognized the full extent of their utility. Whether your business is using Bitcoin as a hedge against traditional currencies, trying to avoid the exorbitant fees charged by financial services institutions, or just looking for an efficient way…
gorodenkoff Investment Thesis Veeva Systems Inc. (NYSE:VEEV) stock is well-placed with lower expectations, as it heads to report its fiscal Q3 2024 results, expected post-market on Wednesday 6 December 2023. I now believe that this is a good entry point for investors to start averaging into their holding of Veeva. For a long time, as…
industryview/iStock via Getty Images Ennis, Inc. (NYSE:EBF) operates within an industry facing decline, yet it distinguishes itself amidst the challenging landscape. Despite the downturn in the commercial printing sector, the company exhibits resilience by leveraging its strong financials. Ennis isn’t positioned as a growth-centric stock; rather, it offers a stable dividend yield and demonstrates potential…
Marcus Lindstrom/iStock via Getty Images Have you heard about Vontier Corporation (NYSE:VNT)? It’s one of those under-the-radar companies that’s been quietly making waves. This year, as the U.S. economy flexed its muscles against rising interest rates, Vontier stood out as a resilient player. I’ve brought this gem to your attention before, suggesting it’s worth keeping…
tianyu wu In this comprehensive analysis, we explore the performance and strategic direction of Eaton Corporation (NYSE:ETN), one of the leading names in power management. Beyond the surface of quarterly earnings, we delve into the company’s business strategy, its response to market trends, and its management of various challenges. Eaton’s ability to deliver impressive financial…
byakkaya Introduction: Q3 earnings, maintaining a buy rating Company background Immunovant (NASDAQ:IMVT), a biopharmaceutical company focusing on autoimmune diseases, continues to show promising developments in its clinical trials and financial stability. Their efforts are primarily centered around batoclimab (IMVT-1401) and IMVT-1402, both FcRn inhibitors. The positive trajectory in their clinical trials, coupled with robust financial…
sturti Overview My recommendation for HireRight Holdings Corporation (NYSE:HRT) is a sell rating. HRT’s recent quarterly results were underwhelming, primarily due to macroeconomic uncertainties, especially the impact of inflation on the hiring landscape. Despite these challenges, HRT’s client hiring patterns remained consistent with past trends, though the overall volume has seen a decline. HRT’s strong…
Brandon Bell Investment action Based on my current outlook and analysis of Campbell Soup Company (NYSE:CPB), I recommend a sell rating. CPB is currently traversing a complex environment marked by poor quarter results, evolving consumer preferences, and strategic moves that present a blend of potential benefits and uncertainties. While select brands under CPB’s umbrella have…
SweetBunFactory Thesis revisit, still maintaining a hold rating FDA Investigation and Stock Implications Recently, BioXcel Therapeutics (NASDAQ:BTAI) has faced regulatory scrutiny with the FDA’s ongoing investigation related to the conduct of one of the TRANQUILITY II study’s primary investigators. An alarming revelation was the issuance of a Form 483 highlighting issues related to the investigator’s…
Lemon_tm At a Glance From a risk-adjusted standpoint, Puma Biotechnology (NASDAQ:PBYI) straddles a precarious line. A flatlining top line, rising operational expenses, and uncertain pipeline prospects, particularly in a competitive kinase inhibitor market set a convoluted stage. The dual red flags of insider selling and moderate short interest add further murkiness to investor sentiment. Until…
Camrocker Intro CVB Financial (NASDAQ:CVBF) is a holding company of Citizens Business Bank, one of the best-performing community banks in California with assets over $16 billion. CVBF has some of the lowest funding costs in the industry which makes it particularly cost-competitive in its core commercial lending business. If the bank manages to maintain this…
imaginima Introduction When I shop, I tend to make quick decisions. If I need shoes, I often buy the first pair that catches my eye in the initial store I visit. My wife, on the other hand, is meticulous. She explores multiple stores, compares prices and features, and ultimately selects the best value. Consequently, she…
kyonntra/E+ via Getty Images Introduction ORIC Pharmaceuticals (NASDAQ:ORIC), a clinical-stage biopharmaceutical company, is dedicated to addressing drug resistance in cancer. Their clinical portfolio includes ORIC-114 for EGFR and HER2 mutations, ORIC-533 targeting CD73 to enhance chemotherapy and immunotherapy, and ORIC-944 for advanced prostate cancer. They are also engaged in early-stage projects to combat various other…
Chris sits down with Julian Liniger from Relai to talk about surviving the bitcoin bear market, what they have been building over the last 12 months, what does Relai hope to accomplish in the near term and what are Julian’s thoughts on new regulations coming to Europe around Cryptocurrencies. Check out the full interview on…
B4LLS Train hard, fight easy.”― John Steele Today, we take our first look at A10 Networks, Inc. (NYSE:ATEN), as this cybersecurity firm goes in the spotlight. This cybersecurity and infrastructure solution provider has been challenged with sales growth so far in 2023, but analyst firms believe revenues will revive in FY2024. The stock has seen…
TERADAT SANTIVIVUT By Brad Tank & Olumide Owolabi Central banks may be reluctant to hike further, but as long as they tie themselves to incoming data their hands may be forced. Given a week to digest the commentary from the Jackson Hole Economic Policy Symposium, market participants are apparently reassured by what they heard. Following…
Torsten Asmus Investment Thesis The SPDR Portfolio TIPS ETF (NYSEARCA:SPIP) has declined by over 20% since the start of the bond bear market in late 2021. As a result, SPIP now trades at 2010 levels after the rapid inflation resurgence in 2021-2022. Sentiment in the Treasury space remains pessimistic due to heavy losses since early…
skynesher Investment Thesis Fidelity National Financial (NYSE:FNF) is an insurance company providing a wide range of insurance, financial services, and technical solutions. Through dedicated investment to diversify the business, FNF has utilized its market-leading position in title insurance to expand. Despite persistent weakness in the commercial real estate market and a still-recovering housing market, FNF…
Dimitrios Kambouris Investment Thesis Despite a Q2 2023 earnings slump attributed to market headwinds, Occidental Petroleum Corporation (NYSE:OXY) has positioned itself for a long-term solid performance by leveraging its diverse portfolio of assets and operational efficiency. The article explores the company’s strategic fundamentals (trifecta strategy), encompassing diverse assets, steady production climb, operational excellence, and commitment…
0meer/iStock via Getty Images Investment Thesis The Trade Desk (NASDAQ:TTD) delivers a mixed report, where its guidance does point to accelerating sequential quarterly growth rates, but for all intents and purposes it appears that for now, The Trade Desk’s growth rates will be stuck at mid-25% CAGR. Given where expectations are, I believe that paying…